Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sentinel Safety Surveillance Not Ideal For Every Product, Reports Find

Executive Summary

Before considering whether to use its nascent Sentinel safety surveillance system, FDA should see whether traditional methods might work just as well, according to two reports commissioned by the agency

You may also be interested in...



Sentinel Will Start Small, FDA Tells IoM; Are Expectations Too Big?

FDA plans to launch two "mini-Sentinel" pilot projects as the next steps towards building the active surveillance capability called for under the FDA Amendments Act of 2007, Sentinel Initiative Scientific Lead Judith Racoosin told a Sept. 2 Institute of Medicine meeting focused on the drug safety system post-FDAAA

Sentinel Will Start Small, FDA Tells IoM; Are Expectations Too Big?

FDA plans to launch two "mini-Sentinel" pilot projects as the next steps towards building the active surveillance capability called for under the FDA Amendments Act of 2007, Sentinel Initiative Scientific Lead Judith Racoosin told a Sept. 2 Institute of Medicine meeting focused on the drug safety system post-FDAAA

Postmarketing Requirements Will Be "Studies" Unless "Trials" Are Needed, FDA Says

Draft guidance lays out the FDAAA-mandated distinction, but also suggests that the agency continues to be much more comfortable with clinical trials than observational studies.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel